Harnessing self-reactivity in cancer immunotherapy

Seminars in Immunology

Volumn 8, Issue 5, 1996, Pages 303-309

  Schoenberger, Stephen P ^a   Sercarz, Eli E ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer immunotherapy; Crypticity; CTL induction; Dominance; Protected T cell repertoires; Self reactivity

Indexed keywords

DIFFERENTIATION ANTIGEN; TUMOR ANTIGEN;

AUTOIMMUNITY; CANCER IMMUNOTHERAPY; REVIEW;

EID: 0030272219     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1006/smim.1996.0039     Document Type: Review

References (44)

1. 1. Boon T, Cerrotini J, van den Eynde B, van der Bruggen P, van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365
2. 2. Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethe B, van den Eynde B, Uyttenhove C, Renauld J-C, Boon T (1995) Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:230-250
3. 3. Gammon G, Shastri N, Cogswell S, Wilbur S, Sadegh-Nasseri S, Krzych U, Miller A, Sercarz E (1987) The choice of T cell epitopes utilized on a protein antigen depends on factors distant from, as well as at, the determinant site. Immunol Rev 98:53-73
4. 4. Gammon G, Sercarz E (1989) How some T cells escape tolerance induction. Nature 342:183-185
5. 5. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Mougdil K (1993) Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11:729-766
6. b-restricted epitopes, submitted
7. 7. Kumar V, Moudgil K, Singh R, Sercarz E (1996) Protected T repertoires, the cryptic self and autoimmunityin New Trends in Immunological Diseases. Academic Press by the Ryoichi Naito Med Res pp49-59
8. 8. Grewal I, Moudgil K, Sercarz E (1995) Hindrance of binding to class II MHC by a single amino acid residue leads to silent crypticity and lack of response to a protein antigen. Proc Natl Acad Sci USA 92:1779-1783
9. 9. Moudgil KD, Grewal IS, Jensen P, Sercarz EE (1996) Unresponsiveness to a self peptide of mouse lysozyme owing to steric hindrance of TCR-MHC/ peptide interaction caused by flanking epitypic residues. J Exp Med 183:535-546
10. 10. Sercarz E, Wilbur S, Sadegh-Nasseri S, Miller A, Manca F, Gammon G, Shastri N (1986) The molecular context of a determinant influences its dominant expression in a T cell response hierarchy through 'fine processing' in Progress in Immunology IV: Sixth International Congress of Immunology 6:227-237
11. 11. Deng H-K, Apple R, Clare-Salzler M, Trembleau S, Mathis D, Adorini L, Sercarz EE (1993) Determinant capture as a mechanism of protection afforded by MHC class II molecules in insulin-dependent diabetes melitus. J Exp Med 178:1675-1680
12. 12. Deng H, Cibotti R, Jamieson B, Clare-Salzler MJ, Hicks C, Guo J, Miller A, Kanellopoulos JM, Sercarz E (1996) The hierarchy of self-determinant presentation in HEL-transgenic mice: negative and positive selection. Submitted
13. 13. Benichou G, Ho PT, Takizawa PA, Killion CC, Olson CA, McMillan M, Sercarz E (1990) Immunogenicity and tolerance of self-MHC peptides. J Exp Med 172:1341-1346
14. 14. Cibotti R, Kanellopoulos J, Cabaniols J-P, Halle-Panenko O, Kosmatopoulos K, Sercarz E, KourilskyP (1992) Tolerance to a self protein involves its immunodominant but not subdominant determinants. Proc Natl Acad Sci USA 89:416-420
15. 15. Lehmann PV, Forsthuber T, Miller A, Sercarz EE (1992) Spreading of T-cell autoimmunity to cryptic determinants of an auto antigen. Nature 358:155-157
16. 16. Kaufman DL, Clare-Salzer M, Tian J, Forsthuber T, Ting GSP, Robinson P, Atkinson MA, Sercarz E, Tobin AJ, Lehmann PV (1993) Spontaneous loss of T cell self tolerance to glutamate decarboxylase is a key event in the pathogenesis of murine insulin-dependent diabetes. Nature 366:69-72
17. 17. McRae BL, Vanerlugt CL, Dal Canto MC, Miller SD (1995) Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182:75-85
18. 18. Yu M, Johnson JM, Tuohy V (1996) A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease. J Exp Med 183:1777-1788
19. 19. Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of strain of origin. Cancer Res 13:835-837
20. 20. Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769-778
21. 21. Hewitt H, Blake E, Walder A (1976) A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 33:241-259
22. 22. Boon T, Van Pel A (1978) Teratocarcinoma cell variants reject by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci USA 75:1519-1524
23. 23. Van Pel A, Vessiere F, Boon T (1983) Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J Exp Med 157:1992-2001
24. 24. Tsomides TJ, Eisen HN (1994) T-cell antigens in cancer. Proc Natl Acad Sci USA 91:3487-3489
25. 25. Houghton AN (1994) Cancer antigens: immune recognition to self and altered self. J Exp Med 180:1-4
26. 26. Visseren MJW, van Elzas A, van der Voort EJH, Ressing ME, Kast WM, Schrier PI, Melief CJM (1995) CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 154:3991-3998
27. 27. van Elzas A, van der Burg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJM, Schrier PI (1996) Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/ MART-1 self antigen. Eur J Immunol 26:1683-1689
28. 28. Bakker AB, Marland G, de Boer AJ, Huijbens RJ, Danen EH, Adema GJ, Figdor CG (1996) Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 55:5330-5334
29. 29. Celis E, Sette A, Grey HM (1995) Epitope selection and development of peptide based vaccines to treat cancer. Semin Cancer Biol 6:329-336
30. 30. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983;9:689-695
31. 31. Rosenberg SA, White DE (1996) Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy J Immunother 19:81-84
32. 32. Hara I, Takechi Y, Houghton AN (1995) Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 182:1609-1614
33. 33. Hu J, Kindsvogel W, Busby S, Bailey MC, Shi Y, Greenberg PD (1993) An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral antigen in normal ymphoid tissues. J Exp Med 177:1681-1690
34. 34. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan, MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. Cell 76:17-27
35. 35. Ashton-Rickardt PG, Bandeira A, Delaney JR, Van Kaer L, Pircher HP, Zinkernagel RM, Tonergawa S (1994) Evidence for a differential avidity model of T cell selection in the thymus. Cell 76:651-663
36. 36. Arnold B, Schönrich G, Hammerling GJ (1993) Multiple levels of peripheral tolerance. Immunol Today 14:12-14
37. 37. Röcken M, Shevach EM (1996) Immune deviation - the third dimension of non-deletional T cell tolerance. Immunol Rev 149:175-194
38. 38. Toes REM, Blom RJJ, Offringa R, Kast WM, Melief CJM (1996) Enhanced tumor outgrowth after peptide vaccination. J Immunol 156:3911-3918
39. 39. Toes REM, Offringa R, Blom RJJ, Melief CJM, Kast WM (1996) Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93:7855-7860
40. 40. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ (1996) p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 93:4781-4786
41. 41. Keetch DW, Andrilole GL (1994) The use of tumor markers in prostate cancer, in Prostate Cancer (Dawson NA, Vogelzang NJ eds) pp95-112. Wiley-Liss, Inc., New York
42. 42. Urban JL, Schreiber H (1992) Tumor antigens. Annu Rev Immunol 10:617-644
43. 43. Melief CJM, Offringa R, Toes REM, Kast WM (1996) Peptide-based cancer vaccines. Current Opin Immunol, in press
44. 44. Thomson SA, Elliot SL, Sherritt MA, Sproat KW, Coupar BEH, Scalzo AA, Forbes CA, Ladhams AM, Mo XY, Tripp RA, Doherty PC, Moss DJ, Suhrbier A (1996) Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol 157:822-826